Analysis of the therapeutic effect of Teritusumab/Telivac

Teritusumab(Teclistamab-cqyv) is an innovative bispecificT cell-engaging antibody specifically designed to treat patients with refractory or relapsed multiple myeloma (MM). Its mechanism simultaneously targets BCMA (B cell maturation antigen) and CD3 molecules on T cells, directly directing the patient's own T cells to tumor cells, thereby activating the T cell killing function and achieving tumor cell clearance. This treatment strategy has shown significant efficacy in multiple myeloma that is difficult to control with conventional chemotherapy.

In clinical studies, teritusumab showed high response rates and sustained anti-tumor effects. The design of the ascending dose regimen ensures the safety of initial administration while laying the foundation for subsequent weekly or biweekly maintenance treatment. After receiving continuous treatment, most patients can obtain partial or complete remission, and the duration of remission is relatively considerable. The efficacy of teritusumab is not only reflected in the reduction in the number of myeloma cells, but also in the improvement of bone marrow function and recovery of blood indicators, thereby significantly improving the patient's quality of life.

In terms of side effects, teritusumab may cause cytokine release syndrome (CRS), injection site reactions and immune-related adverse events, but most of them can be effectively managed through ascending dose regimens, hospitalization and symptomatic treatment. Clinical data shows that standardized dosing and monitoring measures can reduce risks while maximizing efficacy. Compared with traditional chemotherapy, teritusumab, as an immunotherapy method, has the advantages of strong targeting, controllable side effects and sustained anti-tumor activity.

In addition, the dosing flexibility of teritusumab is also one of its therapeutic advantages. For patients who maintain complete remission for at least six months, the dosing frequency can be adjusted to once every two weeks, which not only ensures the efficacy but also reduces the patient's burden of medical visits. This personalized treatment strategy embodies the concept of precision immunotherapy and combines drug efficacy with patient quality of life.

Reference materials:https://www.tecvayli.com/